{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-026336","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.202296+00:00","generated_at":"2026-06-05T19:45:00.508160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edgewise posts Q4 net loss $0.47/sh; pro-forma cash >$550M; multiple trial readouts in 2024","bullets":["Net loss for Q4 2023 was $30.1M ($0.47 per share), up from $25.7M ($0.41) in Q3 2023.","Cash, equivalents and marketable securities $318.4M at Dec 31, 2023; pro-forma >$550M after $231.8M net Jan 2024 offering.","R&D expenses $27.7M (+$3.9M QoQ); G&A $6.2M (+$0.5M QoQ) as clinical programs advanced.","Expect CANYON (Becker) data Q4 2024; ARCH 24-month, DUNE, and LYNX dose data in Q2 2024.","EDG-7500 Phase 1 data and Phase 2 obstructive HCM data expected Q3 2024; FOX trial dosing starts early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-026336","json":"https://secwatch.observer/filing/0001104659-24-026336.json","markdown":"https://secwatch.observer/filing/0001104659-24-026336.md","text":"https://secwatch.observer/filing/0001104659-24-026336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/0001104659-24-026336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/tm246960d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:45:00.508160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db2d2efbb663989949129a07898ed824cd893ea1","claim":"Edgewise Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/0001104659-24-026336-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}